First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. Issue 1 (18th February 2019)

• Record Type: Journal Article
• Authors: Kampstra, Nynke A; Grutters, Jan C; van Beek, Frouke T; Culver, Daniel A; Baughman, Robert P; Renzoni, Elisabetta A; Wuyts, Wim; Kouranos, Vaslis; Wijsenbeek, Marlies S; Biesma, Douwe H; van der Wees, Philip J; van der Nat, Paul B
• Is Part Of: BMJ open respiratory research. Volume 6:Issue 1(2019)
• Publication Date: 2019-02-18
• Subjects: pulmonary sarcoidosis -- value-based healthcare -- outcomes; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; Respiratory therapy -- Periodicals; 616.2005
• DOI: 10.1136/bmjresp-2018-000394
• Languages: English
• ISSNs: 2052-4439

Abstract

Abstract : Introduction: Routine and international comparison of clinical outcomes enabling identification of best practices for patients with pulmonary sarcoidosis is lacking. The aim of this study was to develop a standard set of outcome measures for pulmonary sarcoidosis, using the value-based healthcare principles. Methods: Six expert clinics for interstitial lung diseases in four countries participated in a consensus-driven RAND-modified Delphi study. A mixed-method approach was applied for the identification of an outcome measures set and initial conditions for patients with pulmonary sarcoidosis. The expert team consisted of multidisciplinary professionals (n=14) from Cleveland Clinic, Cincinnati MC, Erasmus MC, Leuven UZ, Royal Brompton and St. Antonius Hospital. During a ranking process, participants were instructed to rank variables on a scale from 1 to 10 based on whether it has (1) impact of the outcome on quality of life, (2) impact of quality of care on the outcome and (3) the number of patients negatively affected by the outcome. Results: An outcome measures set was defined consisting of seven outcome measures: mortality, pulmonary function, soluble interleukin-2 receptor change as an activity biomarker, weight gain, quality of life, osteoporosis and clinical outcome status. Discussion: Collecting outcomes in pulmonary sarcoidosis internationally and the use of a broadly accepted set can enable international comparison. Differences in outcomes can potentially be used as a starting point for quality improvement initiatives.